참고문헌
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185. https://doi.org/10.1016/j.jhep.2012.02.010
- Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. https://doi.org/10.3350/cmh.2012.18.2.109
- Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S112-S121. https://doi.org/10.1002/hep.22920
- Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006;11:669-679.
- Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893. https://doi.org/10.1002/hep.23785
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662. https://doi.org/10.1002/hep.23190
- Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49(5 Suppl):S174-S184. https://doi.org/10.1002/hep.22900
- Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011;53:1854-1863. https://doi.org/10.1002/hep.24318
- Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. https://doi.org/10.1053/j.gastro.2003.09.033
- Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-1391. https://doi.org/10.1002/hep.21189
- Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006;55:1488-1495. https://doi.org/10.1136/gut.2005.077099
- Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-313. https://doi.org/10.1002/hep.21534
- Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514. https://doi.org/10.1002/hep.22841
- Kim HJ, Park JH, Park DI, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-1380. https://doi.org/10.1111/j.1440-1746.2010.06381.x
- Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010;82:1835-1842. https://doi.org/10.1002/jmv.21898
- Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143. https://doi.org/10.1053/j.gastro.2010.10.011
- Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773. https://doi.org/10.1002/hep.24078
- Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254. https://doi.org/10.1136/gut.2010.223206
- van Bommel F, de Man RA, Wedemeyer H, et al. Longterm efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80. https://doi.org/10.1002/hep.23246
- Kim YJ, Sinn DH, Gwak GY, et al. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012;18:6996-7002. https://doi.org/10.3748/wjg.v18.i47.6996
- Shin SR, Yoo BC, Choi MS, et al. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B. Hepatol Int 2011;5:664-670. https://doi.org/10.1007/s12072-010-9238-7
- Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004;9:353-363.
- Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272. https://doi.org/10.1016/S1542-3565(04)00017-5
- van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425. https://doi.org/10.1002/hep.20464
- Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int 2008;2:244-249. https://doi.org/10.1007/s12072-008-9045-6
- van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-325. https://doi.org/10.1002/hep.21253
- Qi X, Xiong S, Yang H, Miller M, Delaney WEt. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362.
- Delaney WEt, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-2477. https://doi.org/10.1128/AAC.00138-06
- Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012;56:520-526. https://doi.org/10.1016/j.jhep.2011.09.018
- Tujios SR, Lee WM. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013;29:250-256. https://doi.org/10.1097/MOG.0b013e32835ff1e9
- Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005;48:133-137. https://doi.org/10.1159/000081740
- Cho JH, Yoon KH, Lee KE, et al. Distribution of hepatitis B virus genotypes in Korea. Korean J Hepatol 2009;15:140-147. https://doi.org/10.3350/kjhep.2009.15.2.140
- Lee JM, Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-241. https://doi.org/10.3851/IMP1510
피인용 문헌
- Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B? vol.30, pp.1, 2015, https://doi.org/10.3904/kjim.2015.30.1.23
- Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis vol.2016, pp.None, 2015, https://doi.org/10.1155/2016/3435965
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy vol.22, pp.2, 2015, https://doi.org/10.3350/cmh.2015.0053
- Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B? vol.22, pp.2, 2016, https://doi.org/10.3350/cmh.2016.0103
- Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study vol.130, pp.8, 2017, https://doi.org/10.4103/0366-6999.204107
- Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study vol.11, pp.1, 2015, https://doi.org/10.5009/gnl15597
- Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea vol.12, pp.1, 2017, https://doi.org/10.1371/journal.pone.0170362
- Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification vol.59, pp.3, 2015, https://doi.org/10.3349/ymj.2018.59.3.383
- Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate vol.98, pp.50, 2015, https://doi.org/10.1097/md.0000000000018351
- Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review vol.55, pp.5, 2015, https://doi.org/10.1007/s00535-020-01680-0
- Tenofovir disoproxil fumarate for patients with chronic hepatitis B who suboptimal response to non‐tenofovir disoproxil fumarate nucleos(t)ide analogs therapy vol.7, pp.4, 2015, https://doi.org/10.1002/aid2.13171
- Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study vol.27, pp.12, 2015, https://doi.org/10.1111/jvh.13363
- Guidelines for Prevention and Treatment of Chronic Hepatitis B vol.n, pp.None, 2015, https://doi.org/10.14218/jcth.2021.00209